Related Experiment Video
Updated: Jan 25, 2026

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
Published on: November 18, 2019
Diagnostic performance of biomarkers for ovarian cancer: Protocol for an overview, evidence mapping, and adjusted
Jinyong Hua1, Jing Liu2, Mengge Hua2
1Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou.
Background:
Ovarian cancer is one of the deadliest gynecological diseases and the annual mortality of ovarian cancer continues to rise. The prognosis of ovarian cancer is poor because it is prone to early metastasis during progression. Therefore, early diagnosis of ovarian cancer is very important. Some systematic reviews have evaluated the diagnostic value of different biomarkers for ovarian cancer. However, there is no consensus in the conclusions, and some are even contradictory. This study aims to assess the methodological and reporting quality of available systematic reviews and to find an optimal biomarker for diagnosing ovarian cancer.
Methods:
The PubMed, Embase.com, the Cochrane Library of Systematic Reviews, and Web of Science were searched to identify relevant systematic reviews from inception to February 2019. We included systematic reviews that include randomized controlled trials, cross-sectional studies, case-control studies, or cohort studies as long as the systematic reviews evaluated the diagnostic performance of biomarkers for ovarian cancer. The methodological quality will be assessed using assessment of multiple systematic reviews-2 checklist, and the reporting quality will be assessed using preferred reporting items for systematic reviews and meta-analysis diagnostic test accuracy (PRISMA-DTA) checklist. The pairwise meta-analysis and indirect comparisons will be performed using STATA (13.0; Stata Corporation, College Station, TX).
Results:
The results of this overview will be submitted to a peer-reviewed journal for publication.
Conclusion:
This overview will provide comprehensive evidence of different biomarkers for diagnosing ovarian cancer.
Prospero Registration Number:
CRD42019125880.
More Related Videos
10:21A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions
Published on: March 3, 2023
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Related Concept Videos
The Evidence for Evolution
Adjusting a Traverse
The Anchoring-and-Adjustment Heuristic
Indirect Motor Pathways
The vestibulospinal tract originates in the vestibular nuclei of the brainstem. The vestibular system detects changes in...
The Sense of Self: Reflected Self-Appraisal and Social Comparison
EDTA: Indirect and Alkalimetric Titration